<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04329000</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKSBE01</org_study_id>
    <nct_id>NCT04329000</nct_id>
  </id_info>
  <brief_title>On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.</brief_title>
  <official_title>The Impacts of On-demand Versus Continuous Esomeprazole Therapy on the Symptom Control and Histological Changes of Metaplastic Esophageal Epithelium in Patients With Barrett's Esophagus (EsoBE) â€” a Multicentre Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      On-demand PPI therapy is feasible for the long-term treatment of patients with Barrett's
      esophagus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutive patients with symptomatic Barrett's esophagus are recruited and receive biopsy
      for esophageal metaplastic mucosa and gastric mucosa over the antrum and body during
      endoscopy on enrollment. The biopsy protocol for esophageal metaplastic mucosa is following
      Seattle protocol. GERD Q score will be conducted on enrollment. Additionally, blood sampling
      for CYP2C19 genotyping is also conducted on enrollment. The eligible subjects will be treated
      by 8-week esomeprazole, and are then randomly assigned to receive either maintenance or
      on-demand esomeprazole therapy (40 mg q.d.) for 40 weeks. The patients were asked to come
      back every four weeks for the recording of symptom days and PPI tablet consumption numbers.
      Follow-up endoscopy with biopsy for esophageal and gastric mucosa is performed at the end of
      the 48th weeks. We will compare the effects of maintenance and on-demand PPI therapy on (1)
      histological changes of esophageal metaplastic mucosa (2) symptom control (3) tablet
      consumption number
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2010</start_date>
  <completion_date type="Actual">December 8, 2019</completion_date>
  <primary_completion_date type="Actual">February 13, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of progression, remaining unchanged, or regression of the distal esophageal metaplastic mucosa in both groups after 48 weeks</measure>
    <time_frame>48 weeks.</time_frame>
    <description>Progression, stationary, regression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total symptom day</measure>
    <time_frame>48 weeks</time_frame>
    <description>Days with reflux symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of tablets consumed</measure>
    <time_frame>48 weeks</time_frame>
    <description>PPI tablets consumed during follow-up</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Barrett Esophagus</condition>
  <condition>Proton Pump Inhibitor</condition>
  <condition>Symptom</condition>
  <condition>Reflux</condition>
  <arm_group>
    <arm_group_label>On-demand PPI therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in this group were advised to take PPI for 8 weeks continuously, followed by on-demand PPI therapy for the following 40 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous PPI therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this group were advised to take PPI QD continuously for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg</intervention_name>
    <description>On-demand Esomeprazole 40 mg QD</description>
    <arm_group_label>On-demand PPI therapy</arm_group_label>
    <other_name>nexium 40 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Continuous Esomeprazole 40 mg QD</description>
    <arm_group_label>Continuous PPI therapy</arm_group_label>
    <other_name>nexium 40 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients between the ages of 20 and 80 years

          -  having symptoms of acid regurgitation, heart burn, or feeling of acidity in the
             stomach

          -  having Barrett's Esophagus proven by histology confirmation

          -  length of esophageal metaplastic mucosa equal to or longer than 1 centimeter

        Exclusion Criteria:

          -  pregnancy,

          -  coexistence of serious concomitant illness (for example, decompensated liver cirrhosis
             and uremia)

          -  previous gastric surgery,

          -  allergic to esomeprazole,

          -  presence of dysplastic esophageal mucosa

          -  equivocal endoscopic diagnosis of Barrett's esophagus
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SUNG-SHUO KAO, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <reference>
    <citation>Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008 Oct 16;359(16):1700-7. doi: 10.1056/NEJMcp0804684. Review.</citation>
    <PMID>18923172</PMID>
  </reference>
  <reference>
    <citation>Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943.</citation>
    <PMID>16928254</PMID>
  </reference>
  <reference>
    <citation>Attwood SE, Lundell L, Hatlebakk JG, Eklund S, Junghard O, Galmiche JP, Ell C, Fiocca R, Lind T. Medical or surgical management of GERD patients with Barrett's esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg. 2008 Oct;12(10):1646-54; discussion 1654-5. doi: 10.1007/s11605-008-0645-1. Epub 2008 Aug 16.</citation>
    <PMID>18709511</PMID>
  </reference>
  <reference>
    <citation>Kastelein F, Spaander MC, Steyerberg EW, Biermann K, Valkhoff VE, Kuipers EJ, Bruno MJ; ProBar Study Group. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2013 Apr;11(4):382-8. doi: 10.1016/j.cgh.2012.11.014. Epub 2012 Nov 28.</citation>
    <PMID>23200977</PMID>
  </reference>
  <reference>
    <citation>Laine L, Ahnen D, McClain C, Solcia E, Walsh JH. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2000 Jun;14(6):651-68. Review.</citation>
    <PMID>10848649</PMID>
  </reference>
  <reference>
    <citation>Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, Jankowski JA, Junghard O, Lundell L, Tytgat GN, Vieth M. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C &amp; M criteria. Gastroenterology. 2006 Nov;131(5):1392-9. Epub 2006 Aug 16.</citation>
    <PMID>17101315</PMID>
  </reference>
  <reference>
    <citation>Gatenby PA, Ramus JR, Caygill CP, Shepherd NA, Watson A. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol. 2008;43(5):524-30. doi: 10.1080/00365520701879831.</citation>
    <PMID>18415743</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Sung-shuo Kao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Barrett's Esophagus</keyword>
  <keyword>Erosive esophagitis</keyword>
  <keyword>Proton pump inhibitor</keyword>
  <keyword>On-demand therapy</keyword>
  <keyword>Continuous therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04329000/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

